DÄ internationalArchive33/2007Isolated Limb Perfusion with Tumor Necrosis Factor-Alpha and Melphalan

Review article

Isolated Limb Perfusion with Tumor Necrosis Factor-Alpha and Melphalan

Dtsch Arztebl 2007; 104(33): A-2268

Schlag, P M; Tunn, P

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics. Cancer J Clin 2001; 51: 15–36. MEDLINE
2. Mankin HJ, Hornicek FJ: Diagnosis, classification, and management of soft tissue sarcomas. Cancer Control 2005; 12: 5–21. MEDLINE
3. Hohenberger P, Tunn PU: Isolated limb perfusion with rhTNF-alpha and melphalan for locally recurrent childhood synovial sarcoma of the limb. J Pediatr Hematol Oncol 2003; 25: 905–9. MEDLINE
4. Carswell EA, Old LJ, Kassel RL: An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666–70. MEDLINE
5. Lejeune FJ, Lienard D, Matter M, Rüegg C: Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 2006; 6: 6. MEDLINE
6. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ: Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998; 4: 408–14. MEDLINE
7. De Wilt JH, ten Hagen TLM, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM: Tumor necrosis factor alpha increases melphalan concentration in tumor tissue after isolated limb perfusion. Brit J Cancer 2000; 82: 1000–3. MEDLINE
8. Creech O Jr, Krementz ET, Ryan RF, Winblad JN: Chemotherapy of cancer: regional perfusion utilizing an extracorporal circuit. Ann Surg 1958; 148: 616–32. MEDLINE
9. Grünhagen DJ, de Wilt JHW, ten Hagen TLM, Eggermont AM: Technology insight: utility of a TNF-a-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Cancer 2006; 106: 1776–84.
10. Eggermont AM, de Wilt JHW, ten Hagen TLM: Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003; 4: 429–37. MEDLINE
11. Lienard D, Eggermont AMM, Schraffordt Koops H et al.: Isolated limb perfusion with tumor-necrosis-factor-alpha and melphalan with or without interferon-gamma for the treatment of intransit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9: 491–502. MEDLINE
12. Grünhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JHW, Eggermont AM: One hundred consecutive isolated limb perfusions with TNF-a and melphalan in melanoma patients with multiple intransit metastases. Ann Surg 2004; 240: 939–48. MEDLINE
13. Lienard D, Delmotte JJ, Renard N, Ewalenko P, Lejeune FJ: High-dose recombinant tumor-necrosis-factor-alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52–60. MEDLINE
14. Eggermont AM, Schraffordt Koops H, Klausner JM et al.: Isolated limb perfusion with tumour-necrosis-factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224: 756–65. MEDLINE
15. Bonvalot S, Laplanche A, Lejeune F et al.: Limb salvage with isolated perfusion of soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol 2005; 16: 1061–8. MEDLINE
16. Grünhagen DJ, de Wilt JH, Graveland WJ, Verhoef C, van Geel AN, Eggermont AM: Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor-necrosis-factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006; 106: 1776–84. MEDLINE
17. Lev-Chelouche D, Abu-Abeid S, Kollender Y et al.: Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high dose tumor-necrosis-factor and melphalan. J Surg Oncol 1999; 70: 185–9. MEDLINE
18. Wieberding J, Benckhuijsen C, Braat RP et al.: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905–10.
19. Lejeune FJ, Pujol N, Nienard D, Mosimann F, Raffoul W, Genton A: Limb salvage by neoadjuvant isolated perfusion with TNF-alpha and melphalan for non resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 2000; 26: 669–78. MEDLINE
20. Olieman AF, Pras E, van Ginkel RJ, Molenaar WM, Schraffordt-Koops H, Hoekstra HJ: Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft tissue sarcoma. Int J Radiol Oncol Biol Phys 1998; 40: 807–14. MEDLINE
21. Kettelhack C, Wickede M, Vogl T, Schneider U, Hohenberger P: 31Phosphorus-magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors. Cancer 2002; 94: 1557–64. MEDLINE
22. Grünhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM: Isolated limb perfusion with tumor-necrosis-factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg. Ann Surg Oncol 2005; 12: 473–9. MEDLINE
23. Eggermont AM et al.: Limb salvage by isolation limb perfusion with tumor-necrosis-factor-alpha and melphalan for locally advanced extremity soft tissue sarcomas: results of 270 perfusions in 246 patients. Proc Am Soc Clin Oncol 1999; 11: 497.

Info

Specialities